🚀 VC round data is live in beta, check it out!
PharmaNutra Valuation Multiples
Discover revenue and EBITDA valuation multiples for PharmaNutra and similar public comparables like Tempo Scan Pacific, Aarti Pharmalabs, Scitop Bio-tech, Sido Muncul and more.
PharmaNutra Overview
About PharmaNutra
PharmaNutra SpA is a pharmaceutical company. The company is engaged in the research, design, development, and marketing of nutraceutical supplements and medical devices. The products of the company include SiderAL Folic, UltraMag, Cetilar, and others. The company operates in Europe, the Middle East, South America, the Far East, Asia and others.
Founded
2003
HQ
Employees
118
Website
Financials (LTM)
EV
$775M
PharmaNutra Financials
PharmaNutra reported last 12-month revenue of $157M and EBITDA of $41M.
In the same LTM period, PharmaNutra generated $41M in EBITDA and $24M in net income.
Revenue (LTM)
PharmaNutra P&L
In the most recent fiscal year, PharmaNutra reported revenue of $135M and EBITDA of $37M.
PharmaNutra expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $157M | XXX | $135M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $96M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $41M | XXX | $37M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 28% | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $24M | XXX | $19M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | — | — | $8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
PharmaNutra Stock Performance
PharmaNutra has current market cap of $776M, and enterprise value of $775M.
Market Cap Evolution
PharmaNutra's stock price is $80.89.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $775M | $776M | 0.3% | XXX | XXX | XXX | $2.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPharmaNutra Valuation Multiples
PharmaNutra trades at 4.9x EV/Revenue multiple, and 18.8x EV/EBITDA.
EV / Revenue (LTM)
PharmaNutra Financial Valuation Multiples
As of March 19, 2026, PharmaNutra has market cap of $776M and EV of $775M.
Equity research analysts estimate PharmaNutra's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PharmaNutra has a P/E ratio of 32.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $776M | XXX | $776M | XXX | XXX | XXX |
| EV (current) | $775M | XXX | $775M | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 5.7x | XXX | XXX | XXX |
| EV/EBITDA | 18.8x | XXX | 20.9x | XXX | XXX | XXX |
| EV/EBIT | 21.6x | XXX | 24.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 8.1x | XXX | XXX | XXX |
| P/E | 32.3x | XXX | 40.5x | XXX | XXX | XXX |
| EV/FCF | 35.5x | XXX | 41.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PharmaNutra Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
PharmaNutra Margins & Growth Rates
PharmaNutra's revenue in the last 12 month grew by 15%.
PharmaNutra's revenue per employee in the last FY averaged $1.3M.
PharmaNutra's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PharmaNutra's rule of X is 63% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
PharmaNutra Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 26% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
PharmaNutra Public Comps
See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Tempo Scan Pacific | XXX | XXX | XXX | XXX | XXX | XXX |
| Aarti Pharmalabs | XXX | XXX | XXX | XXX | XXX | XXX |
| Scitop Bio-tech | XXX | XXX | XXX | XXX | XXX | XXX |
| Sido Muncul | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PharmaNutra M&A Activity
PharmaNutra acquired XXX companies to date.
Last acquisition by PharmaNutra was on XXXXXXXX, XXXXX. PharmaNutra acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by PharmaNutra
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPharmaNutra Investment Activity
PharmaNutra invested in XXX companies to date.
PharmaNutra made its latest investment on XXXXXXXX, XXXXX. PharmaNutra invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by PharmaNutra
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PharmaNutra
| When was PharmaNutra founded? | PharmaNutra was founded in 2003. |
| Where is PharmaNutra headquartered? | PharmaNutra is headquartered in Italy. |
| How many employees does PharmaNutra have? | As of today, PharmaNutra has over 118 employees. |
| Is PharmaNutra publicly listed? | Yes, PharmaNutra is a public company listed on Borsa Italiana. |
| What is the stock symbol of PharmaNutra? | PharmaNutra trades under PHN ticker. |
| When did PharmaNutra go public? | PharmaNutra went public in 2017. |
| Who are competitors of PharmaNutra? | PharmaNutra main competitors are Tempo Scan Pacific, Aarti Pharmalabs, Scitop Bio-tech, Sido Muncul. |
| What is the current market cap of PharmaNutra? | PharmaNutra's current market cap is $776M. |
| What is the current revenue of PharmaNutra? | PharmaNutra's last 12 months revenue is $157M. |
| What is the current revenue growth of PharmaNutra? | PharmaNutra revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of PharmaNutra? | Current revenue multiple of PharmaNutra is 4.9x. |
| Is PharmaNutra profitable? | Yes, PharmaNutra is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PharmaNutra? | PharmaNutra's last 12 months EBITDA is $41M. |
| What is PharmaNutra's EBITDA margin? | PharmaNutra's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of PharmaNutra? | Current EBITDA multiple of PharmaNutra is 18.8x. |
| What is the current FCF of PharmaNutra? | PharmaNutra's last 12 months FCF is $22M. |
| What is PharmaNutra's FCF margin? | PharmaNutra's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of PharmaNutra? | Current FCF multiple of PharmaNutra is 35.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.